Display options
Cite
Anakwue RC, Onwubere BJ, Ikeh V, et al. Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease. Ther Clin Risk Manag. 2015;11:189-200doi: 10.2147/TCRM.S68752.
Anakwue, R. C., Onwubere, B. J., Ikeh, V., Anisiuba, B., Ike, S., & Anakwue, A. M. (2015). Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease. Therapeutics and clinical risk management, 11189-200. https://doi.org/10.2147/TCRM.S68752
Anakwue, Raphael C, et al. "Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease." Therapeutics and clinical risk management vol. 11 (2015): 189-200. doi: https://doi.org/10.2147/TCRM.S68752
Anakwue RC, Onwubere BJ, Ikeh V, Anisiuba B, Ike S, Anakwue AM. Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease. Ther Clin Risk Manag. 2015 Feb 05;11:189-200. doi: 10.2147/TCRM.S68752. eCollection 2015. PMID: 25709461; PMCID: PMC4332259.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2015 Feb 05;11:189-200. doi: 10.2147/TCRM.S68752. eCollection 2015.

Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease.

Therapeutics and clinical risk management

Raphael C Anakwue, Basden J Onwubere, Vincent Ikeh, Benedict Anisiuba, Samuel Ike, Angel-Mary C Anakwue

Affiliations

  1. Department of Pharmacology and Therapeutics, University of Nigeria, Nsukka, Enugu State, Nigeria ; Department of Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.
  2. Department of Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.
  3. Department of Radiography and Radiological Sciences, Imaging Unit, College of Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.

PMID: 25709461 PMCID: PMC4332259 DOI: 10.2147/TCRM.S68752

Abstract

INTRODUCTION: Thyrotoxicosis is an endocrine disorder with prominent cardiovascular manifestations. Thyroid hormone acts through genomic and non-genomic mechanisms to regulate cardiac function. Echocardiography is a useful, non-invasive, easily accessible, and affordable tool for studying the structural and physiological function of the heart.

AIM: We studied thyrotoxicosis patients in a Nigerian Teaching Hospital and employed trans-thoracic echocardiography to find out if there were abnormalities in the hearts of these patients.

METHODS: Fifty adult thyrotoxicosis patients diagnosed with clinical and thyroid function tests in the medical out-patient unit of the hospital were recruited and we performed transthoracic echocardiography with a Sonos 2000 HP machine.

RESULTS: We documented the presence of abnormalities in the following proportion of thyrotoxicosis patients: left ventricular enhanced systolic function in 30%, enhanced diastolic function in 34%, diastolic dysfunction in 34%, heart failure with preserved ejection fraction in10%, heart failure with reduced ejection fraction in 6%, and left ventricular hypertrophy in 34%.

CONCLUSION: Echocardiography was useful in the stratification of cardiac function abnormalities and is indispensable as a guide in the choice of therapeutic options in patients with thyrocardiac disease. The finding of left ventricular enhanced systolic and diastolic functions signify early echocardiographic detectable cardiac abnormalities in thyrotoxicosis, and the clinical management includes the use of anti-thyroid drugs and β-adrenoceptor blockade. Diastolic dysfunction in thyrotoxicosis patients asymptomatic for cardiac disease should be treated with anti-thyroid drugs, and β-adrenoceptor blockade. The judicious application of clinical therapeutics will guide the use of anti-thyroid drugs, diuretics, digoxin, angiotensin inhibitors, and β-adrenoceptor blockade in the successful management of thyrotoxicosis patients with heart failure and reduced, preserved, or increased ejection fraction: parameters which are derived from echocardiography.

Keywords: echocardiography; left ventricle; therapeutics; thyrocardiac disease; thyrotoxicosis

References

  1. Vascul Pharmacol. 2010 Mar-Apr;52(3-4):151-6 - PubMed
  2. J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67 - PubMed
  3. Horm Res. 2003;59 Suppl 1:114-8 - PubMed
  4. Heart. 1996 Apr;75(4):363-8 - PubMed
  5. Clin Endocrinol (Oxf). 1990 Mar;32(3):363-72 - PubMed
  6. J Am Coll Cardiol. 1991 Jun;17(7):1517-9 - PubMed
  7. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 May;43(3):462-6 - PubMed
  8. Circulation. 1997 Jul 15;96(2):592-8 - PubMed
  9. N Engl J Med. 2001 Feb 15;344(7):501-9 - PubMed
  10. Anesth Analg. 1997 Oct;85(4):734-8 - PubMed
  11. Pol Arch Med Wewn. 2001 Feb;105(2):131-8 - PubMed
  12. Int J Cardiol. 2003 Aug;90(2-3):159-64 - PubMed
  13. Niger J Med. 2001 Apr-Jun;10(2):50-4 - PubMed
  14. Thyroid. 2002 Jun;12(6):459-66 - PubMed
  15. Circ Res. 1999 Sep 17;85(6):498-503 - PubMed
  16. QJM. 2009 Apr;102(4):235-41 - PubMed
  17. Br Heart J. 1981 Aug;46(2):137-43 - PubMed
  18. Am J Med. 1990 Jul;89(1):122-3 - PubMed
  19. N Engl J Med. 1979 Feb 15;300(7):353-4 - PubMed
  20. Congest Heart Fail. 2003 Jan-Feb;9(1):40-6 - PubMed
  21. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):533-8 - PubMed
  22. Minerva Endocrinol. 2004 Sep;29(3):139-50 - PubMed
  23. Am J Med. 1992 Jul;93(1):61-8 - PubMed
  24. Circ Res. 1999 Jul 9;85(1):e1-6 - PubMed
  25. JAMA. 1994 Apr 27;271(16):1276-80 - PubMed
  26. J Endocrinol. 1971 Jan;49(1):167-73 - PubMed
  27. Circ Res. 1994 Aug;75(2):245-51 - PubMed
  28. Br J Clin Pharmacol. 1998 Nov;46(5):421-4 - PubMed
  29. J Clin Endocrinol Metab. 2005 Feb;90(2):673-7 - PubMed
  30. Clin Endocrinol (Oxf). 2011 May;74(5):636-43 - PubMed
  31. J Clin Invest. 1967 Oct;46(10):1669-82 - PubMed
  32. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5251-5 - PubMed
  33. J Am Vet Med Assoc. 1988 Jun 1;192(11):1546-9 - PubMed
  34. Eur J Clin Pharmacol. 1977 Dec 28;12(6):437-43 - PubMed
  35. J Clin Endocrinol Metab. 1991 Jul;73(1):146-50 - PubMed
  36. N Engl J Med. 1992 Jul 9;327(2):94-8 - PubMed
  37. Cor Vasa. 1992;34(2):108-14 - PubMed
  38. J Am Coll Cardiol. 2001 Mar 15;37(4):1042-8 - PubMed
  39. Lancet. 1999 Jan 2;353(9146):9-13 - PubMed
  40. J Am Coll Cardiol. 1986 May;7(5):967-74 - PubMed
  41. Circulation. 2001 Dec 18;104(25):3076-80 - PubMed
  42. Drugs Exp Clin Res. 1990;16(4):167-73 - PubMed
  43. Vasc Health Risk Manag. 2010 Aug 09;6:473-7 - PubMed
  44. Heart. 2007 Apr;93(4):483-7 - PubMed
  45. Curr Treat Options Cardiovasc Med. 2001 Apr;3(2):151-159 - PubMed
  46. Endocr Rev. 2005 Aug;26(5):704-28 - PubMed
  47. Q J Med. 1985 Jan;54(213):19-28 - PubMed
  48. Am Heart J. 1982 Dec;104(6):1303-8 - PubMed
  49. Thyroid. 2002 Jun;12(6):447-52 - PubMed
  50. Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14104-9 - PubMed
  51. Lancet. 1999 Jun 12;353(9169):2001-7 - PubMed
  52. N Engl J Med. 2001 May 31;344(22):1651-8 - PubMed
  53. Metabolism. 1976 Sep;25(9):973-9 - PubMed
  54. J Am Soc Echocardiogr. 2001 Jun;14 (6):601-11 - PubMed
  55. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73-90 - PubMed
  56. Angiology. 2006 Oct-Nov;57(5):600-6 - PubMed
  57. Mol Endocrinol. 1987 Jan;1(1):83-9 - PubMed
  58. Br Med J. 1977 Jun 11;1(6075):1505-7 - PubMed
  59. J Clin Endocrinol Metab. 2002 Mar;87(3):968-74 - PubMed
  60. Am J Med Sci. 1995 Sep;310(3):99-102 - PubMed
  61. Am J Med. 1990 Jun;88(6):642-6 - PubMed
  62. J Clin Endocrinol Metab. 2005 Nov;90(11):6041-7 - PubMed
  63. Compend Contin Educ Vet. 2013 Jul;35(7):E5 - PubMed
  64. Recent Prog Horm Res. 2004;59:31-50 - PubMed
  65. JAMA. 2003 Jan 8;289(2):194-202 - PubMed

Publication Types